SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · InMed Pharmaceuticals entered into Amendment No

InMed Pharmaceuticals Inc. · 8-K filed Jul 10, 2026 at 16:02 ET

At the news

BEARISHIMPACT 6/10

8-K filed Jul 10, 2026 at 16:02 ET

InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal sequencing, tax treatment, and the impact of pre-closing financing on the exchange ratio. The company also filed an S-4 registration statement for the all-stock reverse merger, expected to close in Q4 2026. The transaction effectively transforms InMed into a migraine-focused biotech (Mentari) with a $125M enterprise value for Mentari, but InMed's current shareholders face massive dilution and a reverse stock split to maintain Nasdaq listing.

  • InMed (INM, $5M market cap) entered into Amendment No. 1 to merge with private biotech Mentari Therapeutics in an all-stock reverse merger.
  • Mentari's equity value is set at $125,000,000, implying extreme dilution for current INM shareholders relative to the $5M market cap.
  • The amendment introduces a 'Company PIPE Amendment' to allow additional pre-closing financing, which will further dilute the exchange ratio for INM holders.
  • A Nasdaq Reverse Split is planned before closing to maintain listing compliance.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access